Latest updates for Xbi

Fresh curated links around XBI are collected here so marketers can spot useful updates and turn timely ideas into posts faster.

Recent items include:

  • XBI: Big Pharma Can Keep The 76% Rally Going
  • XLV vs. IBBQ: Is Broad Healthcare Exposure or Biotech Growth the Better ETF Buy?
  • The Investor Mentality

Post angles to try

Share the most useful takeaway for your audience.
Turn one article into a quick practical checklist.
Ask your audience how this shift affects their work.
Turn angles into scheduled posts

Fresh articles and ideas

Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.

seekingalpha.com /4 days ago

XBI: Big Pharma Can Keep The 76% Rally Going

Read source
finance.yahoo.com /1 month ago

XLV vs. IBBQ: Is Broad Healthcare Exposure or Biotech Growth the Better ETF Buy?

Read source
seekingalpha.com /2 weeks ago

The Investor Mentality

Read source
fool.com /1 month ago

XLV vs. IBBQ: Is Broad Healthcare Exposure or Biotech Growth the Better ETF Buy?

IBBQ posted the stronger return over the past year, but has also experienced much higher historical volatility than XLV.

Read source
seekingalpha.com /1 month ago

Playing The Biotech Breakout With Insiders

Read source
seekingalpha.com /3 weeks ago

XBP Global Holdings, Inc. 2026 Q2 - Results - Earnings Call Presentation

Read source
seekingalpha.com /2 weeks ago

Where Is Growth?

Read source
cafepharma.com /1 week ago

BioXcel

BioXcel Anonymous (not verified) Sun, 08/30/2026 - 09:43 field_thread_url https://cafepharma.com/boards/threads/bioxcel.674502/ board na...

Read source
seekingalpha.com /3 weeks ago

XBP Global Holdings, Inc. (XBP) Q2 2026 Earnings Call Prepared Remarks Transcript

Read source
seekingalpha.com /3 weeks ago

Are Biotech Stocks The 'Comeback Kid' Of 2026? I Say Yes

Read source
biopharmadive.com /1 week ago

This week in charts: Biotech’s rebound is undeniable

Not only is the XBI continuing to hover around a historic high, but drug companies can’t seem to get enough of both large IPOs and big-ticket M&A.

Read source
seekingalpha.com /2 weeks ago

Neurocrine Biosciences: 'House Full Of Options'

Read source
seekingalpha.com /1 month ago

Inhibrx Biosciences: The Whole Story Rides On INBRX-106

Read source
seekingalpha.com /1 month ago

ImmunityBio: ANKTIVA's Commercial Momentum Supports A Buy

Read source
seekingalpha.com /1 month ago

SELLAS Life Sciences: Strong Buy-Imminent Catalyst, Dual-Platform Pipeline, And A Market That Hasn't Caught Up

Read source
seekingalpha.com /1 week ago

BioXcel files for Chapter 11, will sell assets to Teva

Read source
seekingalpha.com /1 month ago

Incyte: Profitable Biotech That Could Be Close To Exploding

Read source
finance.yahoo.com /1 month ago

Better Healthcare Sector ETF: Vanguard's Broad VHT vs. Invesco's Biotechnology-Focused IBBQ

Read source
finance.yahoo.com /1 month ago

BXP, Inc. Q2 2026 Earnings Call Summary

Read source
seekingalpha.com /2 weeks ago

TG Therapeutics: Briumvi's Growth Attracts Buyout Rumors

Read source
fool.com /1 month ago

Concentrated Pharma Exposure or Broader Global Healthcare? PPH vs. IXJ

The VanEck Pharmaceutical ETF (PPH) gives investors a concentrated way to own major drugmakers, while the iShares Global Healthcare ETF (IXJ) spreads exposure across the wider heal...

Read source
seekingalpha.com /1 month ago

ImmunityBio: Intriguing Progress, If Not (Yet) Commercially - Still A Hold

Read source
seekingalpha.com /1 month ago

SELLAS Life Sciences: The Ownership Structure Has Changed Before The Defining Catalyst

Read source
newswire.com /1 month ago

Brookmount Explorations Inc. (BMXI) Completes Acquisition of Mentor AI Corp

All-stock acquisition marks the Company's entry into artificial-intelligence technologies

Read source

Turn fresh research into a full content calendar

Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.

Sources covering Xbi

seekingalpha.com

Recent coverage from public sources
Public source

cafepharma.com

Recent coverage from public sources
Public source

finance.yahoo.com

Recent coverage from public sources
Public source

seekingalpha.com

Recent coverage from public sources
Public source

seekingalpha.com

Recent coverage from public sources
Public source

biopharmadive.com

Recent coverage from public sources
Public source